

Jeffrey Secunda
Associate Vice President
Technology & Regulatory Affairs

GS1 HUG[™]
June 6, 2007
Orlando, Florida


AdvaMed Growth



- Founded in 1974 as the Health Industry Manufacturers Association (HIMA)
- Now grown to 1,300 + member companies and subsidiaries (devices, diagnostics, HIS)
- Nearly 90% of domestic market
- \$20 million budget, 60 staff with global expertise
- 45 member Board of Directors

2007 Active Members By Company Size







Goals

- Gaining rapid clearance by FDA
- Ensuring adequate payment
- Speeding coverage determinations
- Accessing international markets



Primary Goal

 Work to ensure an appropriate premarket and postmarket regulatory environment both domestically and globally



2007 Policy Focus

MDUFMA Reauthorization

- Improved Performance
- Stable and Predictable Fees
- Third-Party Review
- Third-Party Inspection
- Appropriate Regulatory Scheme for IVDs

Combination Products

- Cross-Labeling
- Adverse Events
- GMP's

Postmarket

- Risk Communication
- Adverse Event Reporting
- Recalls
- Unique Device Identification
- Post Approval Studies (CoA, 522)
- Annual Reports

Critical Path

- Device Development Models
- Surrogate Endpoints for Drug-Eluting Stents
- Other Initiatives



Standards Involvement

- Member ISO TC 212 Clinical laboratory testing and in vitro diagnostic test systems
- Clinical Laboratory Standards Institute
- Member US National Committee of the IEC Technical Management Committee
- US Technical Advisor for IEC TC 62 and SC 62A IEC 60601-1 general standard for the safety of electrical medical devices, and associated collateral standards US Chief delegate at TC/SC meetings
- Member IEC TC 62 Chairman's Advisory Group main strategy group for international committee
- Co-Chair of AAMI Electrical Safety Committee



Auto-ID Working Group

- Co-chairs: Tom Werthwine (J&J) & Jackie Elkin (Medtronic)
- 90+ Individuals representing 40+ AdvaMed Members Companies
- Support Standards Development: GS/1, EPCglobal, HIBCC
- Oppose legislative proposals to restrict the use of RFID
- Support FDA as the most appropriate vehicle for development and implementation of UDI System



Auto-ID Working Group

- AdvaMed supports the development of Auto-ID technology and standards that address specific patient and public health safety problems
- FDA Stakeholder Meetings on UDI (April, October 2005)
- FDA Public Meeting on UDI (October 2006)
- FDA Docket on UDI (November 2006)



What are the Problems?

- Eastern Research Group Report on UDI (March 2006)
 - Use Error
 - Device interactions
 - Counterfeiting
 - MDR Analysis
 - Recalls Tracking



Attacking the Problem

- Root Cause Analysis
- Risk Analysis
 - Severity
 - Frequency
 - Mitigation
- Solution
 - Device
 - Use
 - Unintended Consequences



Device Characteristics

- Risk Class
- Physical size, material
- Packaging
- Use



Use Characteristics

- Professional
- Self /Family
- Care setting
- Processing Disposable, Reusable



Unintended Consequences

- Technology limitations
- Implementation costs
- Adoption by Users



Elements of Device Identity

- What is it Category
- Who made it Manufacturer
- What was made Model, packaging
- How/When was it made LOT / Serial Number
- Other info expiration, materials, reprocessing, handling



F D A Current Regulations –

- Design & Manufacturing
 - 21 CFR 820 Quality System Regulation
- Labeling
 - 21CFR 801: General Provision for Labeling
 - 21 CFR 801.400 Special Requirements for Specific Devices
 - Section 301: Prominent and Conspicuous Mark of Manufacturers Who Reprocess Single-Use Devices
- Adverse Event Reporting
 - 21 CFR 803: Medical Device Reports (MDR)
- Recalls
 - 21 CFR 806: Corrections & Removals
 - 21 CFR 810: Recall Authority
 - 21 CFR 821: Device Tracking (SMDA:1990)



F D A Current Authority Applicable to UDI

Registration Of Producers Of Drugs And Devices

- **SEC. 510.** [21 U.S.C. 360] (e) "The Secretary may by regulation prescribe a uniform system for the identification of devices intended for human use..."

Misbranded Drugs And Devices

- **SEC. 502.** [21 U.S.C. 352] A drug or device shall be deemed to be misbranded ... (o) "...if it does not bear such symbols from the uniform system for identification of devices prescribed under section 510(e) as the Secretary by regulation requires."



Concluding Points

- 1. Work with all Stakeholders to identify specific safety problems that can be mitigated by the application of Auto-ID
- 2. Support the develop of consensus standards for different modes and applications of Auto-ID
- 3. Propose UDI solutions to patient safety problems, including a clear plan for adoption by device users
- 4. Medical devices are extremely diverse in size, materials, processing, use, and criticality

www.advamed.org



Home | News Room | Contact Us

Advanced Search

SEARCH

About AdvaMed | Issues & Advocacy | Meetings & Events | Membership | Publications | Members Only



Bringing innovation to patient care worldwide



OUICK LINKS

- Philanthropy
- Code of Ethics
- Careers

 Medical Technology Learning Institute

AdvaMed is the world's largest medical



October 1-3, 2007, Washington, DC Ronald Regan Building and International Trade Center



Learn more about the people who advance medical technology.

➤ MEMBERS ONLY

Welcome to our web site!

If you are already an association member or have previously registered, please LOG IN to your account.

Learn how your company can become an AdvaMed member.

➤ NON-MEMBER LOGIN

Non-AdvaMed members can login to:

- Create an account
- Sign-up for publications
- Update information

Upcoming Events and Meetings

Private Payer and other Non-CMS Reimbursement for Medical Technology, June 12-13, 2007, Chicago, IL

Medical Device Clinical Trials and Biosafety Monitoring, June 26-27, Palo Alto, CA

11th Conference of the Global Harmonization Task Force October 3-4, Washington, DC

AdvaMed 2007 Trade Show, October 1-3, Washington, DC



THANK YOU!